Caseware UK (AP4) 2024.0.164 2024.0.164 2024-06-302024-06-302true2023-07-01falsefalseNo description of principal activity2falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 10824253 2023-07-01 2024-06-30 10824253 2022-07-01 2023-06-30 10824253 2024-06-30 10824253 2023-06-30 10824253 c:Director1 2023-07-01 2024-06-30 10824253 d:FurnitureFittings 2023-07-01 2024-06-30 10824253 d:FurnitureFittings 2024-06-30 10824253 d:FurnitureFittings 2023-06-30 10824253 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 10824253 d:ComputerEquipment 2023-07-01 2024-06-30 10824253 d:ComputerEquipment 2024-06-30 10824253 d:ComputerEquipment 2023-06-30 10824253 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 10824253 d:OwnedOrFreeholdAssets 2023-07-01 2024-06-30 10824253 d:FreeholdInvestmentProperty 2024-06-30 10824253 d:FreeholdInvestmentProperty 2023-06-30 10824253 d:CurrentFinancialInstruments 2024-06-30 10824253 d:CurrentFinancialInstruments 2023-06-30 10824253 d:Non-currentFinancialInstruments 2024-06-30 10824253 d:Non-currentFinancialInstruments 2023-06-30 10824253 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 10824253 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 10824253 d:Non-currentFinancialInstruments d:AfterOneYear 2024-06-30 10824253 d:Non-currentFinancialInstruments d:AfterOneYear 2023-06-30 10824253 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-06-30 10824253 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-06-30 10824253 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2024-06-30 10824253 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2023-06-30 10824253 d:ShareCapital 2024-06-30 10824253 d:ShareCapital 2023-06-30 10824253 d:RetainedEarningsAccumulatedLosses 2024-06-30 10824253 d:RetainedEarningsAccumulatedLosses 2023-06-30 10824253 c:FRS102 2023-07-01 2024-06-30 10824253 c:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 10824253 c:FullAccounts 2023-07-01 2024-06-30 10824253 c:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 10824253 2 2023-07-01 2024-06-30 10824253 d:AcceleratedTaxDepreciationDeferredTax 2024-06-30 10824253 d:AcceleratedTaxDepreciationDeferredTax 2023-06-30 10824253 d:TaxLossesCarry-forwardsDeferredTax 2024-06-30 10824253 d:TaxLossesCarry-forwardsDeferredTax 2023-06-30 10824253 e:PoundSterling 2023-07-01 2024-06-30 iso4217:GBP xbrli:pure

Registered number: 10824253










NORTH ESSEX MEDICAL PROPERTIES LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 JUNE 2024

 
NORTH ESSEX MEDICAL PROPERTIES LTD
REGISTERED NUMBER: 10824253

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
2,173
1,185

Investment property
 5 
1,294,999
1,294,999

  
1,297,172
1,296,184

Current assets
  

Debtors: amounts falling due within one year
 6 
-
22,133

Cash at bank and in hand
  
23,416
22,786

  
23,416
44,919

Creditors: amounts falling due within one year
 7 
(90,252)
(104,800)

Net current liabilities
  
 
 
(66,836)
 
 
(59,881)

Total assets less current liabilities
  
1,230,336
1,236,303

Creditors: amounts falling due after more than one year
 8 
(872,093)
(912,087)

Provisions for liabilities
  

Deferred tax
 10 
(52,264)
(38,694)

  
 
 
(52,264)
 
 
(38,694)

Net assets
  
305,979
285,522


Capital and reserves
  

Called up share capital 
  
2
2

Profit and loss account
  
305,977
285,520

  
305,979
285,522


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies
Page 1

 
NORTH ESSEX MEDICAL PROPERTIES LTD
REGISTERED NUMBER: 10824253
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 JUNE 2024

subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 26 March 2025.




................................................
Dr H M Chowhan
Director

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
NORTH ESSEX MEDICAL PROPERTIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

1.


General information

North Essex Medical Properties Limited is a private company and incorporated in England and Wales, registration number 10824253. The registered office is 8 The Courtyard, Wyncolls Road, Severalls Industrial Park, Colchester, CO4 9PE.
The financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest £. 
The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rental income is recognised in the period to which it relates.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 3

 
NORTH ESSEX MEDICAL PROPERTIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

2.Accounting policies (continued)


2.6
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Fixtures & fittings
-
33%
Straight line basis
Computer equipment
-
33%
Straight line basis

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Investment property

Investment property is carried at fair value determined annually by external valuers and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided. Changes in fair value are recognised in profit or loss.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).

Page 4

 
NORTH ESSEX MEDICAL PROPERTIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

4.


Tangible fixed assets





Fixtures & fittings
Computer equipment
Total

£
£
£



Cost or valuation


At 1 July 2023
370
1,407
1,777


Additions
-
2,370
2,370



At 30 June 2024

370
3,777
4,147



Depreciation


At 1 July 2023
123
469
592


Charge for the year on owned assets
123
1,259
1,382



At 30 June 2024

246
1,728
1,974



Net book value



At 30 June 2024
124
2,049
2,173

Page 5

 
NORTH ESSEX MEDICAL PROPERTIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

5.


Investment property


Freehold investment property

£



Valuation


At 1 July 2023
1,294,999



At 30 June 2024
1,294,999

The 2024 valuations were made by the directors, on an open market value for existing use basis.



At 30 June 2024




Page 6

 
NORTH ESSEX MEDICAL PROPERTIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

6.


Debtors

2024
2023
£
£


Trade debtors
-
21,633

Prepayments
-
500

-
22,133



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Bank loans
39,994
38,453

Corporation tax
6,625
7,837

Other taxation and social security
3,525
3,920

Other creditors
38,128
51,846

Accruals and deferred income
1,980
2,744

90,252
104,800



8.


Creditors: Amounts falling due after more than one year

2024
2023
£
£

Bank loans
872,093
912,087

872,093
912,087


The bank loan is secured by a fixed charge of the company's investment properties and a fixed and floating charge on all other assets.

Page 7

 
NORTH ESSEX MEDICAL PROPERTIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

9.


Loans


Analysis of the maturity of loans is given below:


2024
2023
£
£

Amounts falling due within one year

Bank loans
39,994
38,453


39,994
38,453


Amounts falling due 2-5 years

Bank loans
182,138
173,695


182,138
173,695

Amounts falling due after more than 5 years

Bank loans
689,955
738,392

689,955
738,392

912,087
950,540


The bank loan is secured by a fixed and floating charge over all the assets of the company.


10.


Deferred taxation




2024


£






At beginning of year
(38,694)


Charged to profit or loss
(13,570)



At end of year
(52,264)

Page 8

 
NORTH ESSEX MEDICAL PROPERTIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
 
10.Deferred taxation (continued)

The provision for deferred taxation is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(2,848)
(1,138)

Capital gain
(49,416)
(37,556)

(52,264)
(38,694)

 
Page 9